Insider · CIK 0001761487
William G. Rice
Files at APTO (Aptose Biosciences Inc.). First filing Nov 26, 2024, latest Nov 26, 2024.
In brief
William G. Rice files SEC Form 4 as CEO, president, chair and director at APTO (Aptose Biosciences Inc.). Since Nov 26, 2024, William G. Rice has reported 1 open-market buy worth $20k and 0 open-market sells worth $0, the latest filed on Nov 26, 2024.
A track record needs three past buys with six months of prices behind them; William G. Rice has 0, so none is measured yet.
The newest scored trade: bought $20k of APTO on Nov 25, 2024, filed Nov 26, 2024, scored 28 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | APTObuy Aptose Biosciences Inc. | $20k 100,000 shares | +19% | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Common Shares | -613,252 | $1.72 | $1.1M | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Stock Option ("Right to Buy")derivative | -70,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Warrantsderivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Stock Option ("Right to Buy")derivative | -400,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Performance Stock Optionsderivative | -600,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Option Grantderivative | -700,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Stock Option ("Right to Buy")derivative | -343,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Option Grantderivative | -2,000,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Stock Options (Right to Buy)derivative | -400,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Jun 30, 2026 | APTO Aptose Biosciences Inc. | DDisposition to issuer Common Sharesderivative | -400,000 | $0.00 | $0 | 0 | Jul 1, 2026 |
| Nov 25, 2024 | APTO Aptose Biosciences Inc. | POpen-market purchase Common Shares | +100,000 | $0.20 | $20k | 613,252 | Nov 26, 2024 |
| Nov 25, 2024 | APTO Aptose Biosciences Inc. | POpen-market purchase Warrantsderivative | +50,000 | - | - | 50,000 | Nov 26, 2024 |
Questions about William G. Rice
Answered from the filings on this page, as of the latest one.
Is William G. Rice buying or selling?
Not in the last 12 months. William G. Rice's latest open-market trade on SEC Form 4 was bought $20k of APTO on Nov 25, 2024.
How did William G. Rice's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and William G. Rice has 0.
Where does William G. Rice file Form 4?
William G. Rice has filed Form 4 at APTO (Aptose Biosciences Inc.) as Chair, President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.